Improving treatments for antibiotic-resistant bacterial infections
Task C24: Process Optimization and Scale Up of an Antibiotic-Resistant Bacterial Agent
['FUNDING_OTHER'] · ALBANY MOLECULAR RESEARCH, INC. · NIH-11178795
This study is working on creating new treatments for tough infections caused by antibiotic-resistant bacteria, like Acinetobacter and Pseudomonas aeruginosa, to help patients who currently have limited options for effective care.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | ALBANY MOLECULAR RESEARCH, INC. (nih funded) |
| Locations | 1 site (ALBANY, UNITED STATES) |
| Trial ID | NIH-11178795 on ClinicalTrials.gov |
What this research studies
This research focuses on developing new therapeutic agents to combat antibiotic-resistant bacteria, specifically targeting pathogens like Acinetobacter and Pseudomonas aeruginosa. The approach involves optimizing processes for creating these agents, including planning, evaluation, and manufacturing under good practices. The research will also assess the safety and effectiveness of these agents through laboratory testing. Patients may benefit from new treatment options that are effective against infections that are currently difficult to treat due to resistance.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals suffering from infections caused by antibiotic-resistant bacteria.
Not a fit: Patients with infections that are not caused by antibiotic-resistant bacteria may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antibiotics that effectively treat infections caused by resistant bacteria.
How similar studies have performed: Other research has shown promise in developing new antibiotics targeting resistant bacteria, indicating that this approach has potential for success.
Where this research is happening
ALBANY, UNITED STATES
- ALBANY MOLECULAR RESEARCH, INC. — ALBANY, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SCHLAGER, HEIDI — ALBANY MOLECULAR RESEARCH, INC.
- Study coordinator: SCHLAGER, HEIDI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Communicable Diseases, Infectious Disease Pathway, Infectious Diseases, Infectious Disorder